Real-world study of Sintilimab neoadjuvant immunotherapy combined with chemotherapy in patients with non-small cell lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062304

Enrollment

Unknown

Registered

2022-08-01

Start date

2022-07-25

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

NA:sintilimab combined with chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have received Sintilimab neoadjuvant immunotherapy plus chemotherapy and have complete imaging data since 2019; 2. TNM staging in patients with stage IIA-IIIB

Exclusion criteria

Exclusion criteria: 1. Patients whose medical records are not perfect and cannot be properly evaluated; 2. Patients who are still missing are followed up in a variety of ways.

Design outcomes

Primary

Measure	Time frame
Pathological complete remission rate;;;	—

Countries

China

Contacts

Public ContactXixian Ke,Cheng Chen

Zunyi medical university

kexixian@zmu.edu.cn+86 18798679808, +8615085469939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026